<DOC>
<DOCNO>EP-0628312</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Anti-contraceptive composition
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31565	A61K3157	A61K970	A61J103	A61K900	A61P1500	A61K900	A61K31565	A61K3157	A61K970	A61J100	A61P1500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61J	A61K	A61P	A61K	A61K	A61K	A61K	A61J	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K9	A61J1	A61K9	A61P15	A61K9	A61K31	A61K31	A61K9	A61J1	A61P15	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Combination prepn. for contraception contains, as essential element, a mixt. (M) of biogenic oestrogen (I); synthetic oestrogen (II) and a gestagen (III). It opt. includes,. as (a) placebos; (b) biogenic or synthetic (III); (c) (I) or (II)); (d) a mixt. of (I), (II) and (III), or (e) a mixt. of (II) and (III). (I) is (Ia), oestrone, oestrane or oestriol; (II) is (IIa) or (IIb), (III) is (IIIa), desogestrel, progesterone, norethisterone acetate, chlormadinone acetate, gestodene, or cyproterone acetate, or any precursor which rapidly release such cpds. after admin..
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
JENAPHARM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
JENAPHARM GMBH 
&
 CO. KG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DITTGEN MICHAEL PROF
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL MICHAEL PROF
</INVENTOR-NAME>
<INVENTOR-NAME>
OSTERWALD HERMANN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
DITTGEN, MICHAEL, PROF.
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL, MICHAEL, PROF.
</INVENTOR-NAME>
<INVENTOR-NAME>
OSTERWALD, HERMANN, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A combination preparation for contraception,
consisting of one step or of one and several

additional steps, at least one step containing a
combination of three components, namely a biogenic

estrogen, a synthetic estrogen and a gestagen, and
each of the other steps consisting of a

pharmaceutically unobjectionable placebo

or a biogenic or synthetic gestagen,
or a biogenic or synthetic estrogen,
or a combination of three components, namely a
biogenic estrogen, a synthetic estrogen, and a

gestagen
or a combibation of synthetic estrogens and a
gestagen.
A combination preparation according to Claim 1,
characterized by the fact that the biogenic estrogen

has at least one component selected from the group
consisting of estradiol, estrone, estrane, estriol,

or at least one compound which, when administered,
rapidly splits off one of the aforementioned estrogen

components.
A combination preparation according to Claim 1,
characterized by the fact that the synthetic estrogen

has at least one component selected from the group
consisting of ethinyl estradiol, mestranol, or at

least one compound which, when administered, rapidly
splits off one of the aforementioned estrogen

components. 
A combination preparation according to Claim 1,
characterized by the fact that the gestagen has at

least one component selected from the group
consisting of levonorgestrel, desogestrel,

progesterone, norethisterone acetate, chlormadinone
acetate, gestoden, cyproterone acetate, or at least

one compound which, when administered, rapidly splits
off one of the aforementioned gestagen components.
A combination preparation according to Claims 1 to 4
for oral administration.
A combination preparation according to Claims 1 to 4
for intravaginal administration.
A combination preparation according to Claims 1 to 4
for transdermal administration.
A pharmaceutical package for contraception,
characterized by the fact that it contains up to 28

daily dose units of the combination preparation
according to at least one of the preceding claims,

the number of daily dose units of the first step
being 1 to 28 
and, in case of the presence of a
second step, the number of the daily dose units for

the second step being 1 to 14 and, in the case of the
presence of further steps, the number of daily dose

units for such further steps being in each case 1 to
7,

whereby at least one step containing a combination of
three components, namely a biogenic estrogen, a

synthetic estrogen and a gestagen, and each of the
other steps consisting of a pharmaceutically

unobjectionable placebo

or a biogenic or synthetic gestagen,
or a biogenic or synthetic estrogen,
or a combination of three components, namely a 
biogenic estrogen, a synthetic estrogen, and a

gestagen
or a combibation of synthetic estrogens and a
gestagen.
</CLAIMS>
</TEXT>
</DOC>
